Abbreviations & Acronyms BC = bladder cancer BCG = bacillus CalmetteGu erin CIS = carcinoma in situ CSS = cancer-specific survival EAU = European Association of Urology EMT = epithelialmesenchymal transition HG = high-grade HPF = high-power field IQR = interquartile range LVI = lymphovascular invasion NMIBC = non-muscleinvasive bladder cancer OS = overall survival PFS = progression-free survival RC = radical cystectomy TUR = transurethral resection WHO = World Health Organization Objectives: To investigate established prognostic factors and relatively new histopathological tumor characteristics including metric substage and lamina propria invasion patterns in a large series of T1 high-grade non-muscle-invasive bladder cancer. Methods: Between 1989 and 2012, 322 patients with initial stage T1 high-grade bladder cancer underwent transurethral resection, followed by re-transurethral resection and a conservative approach with follow-up regime alone or instillation treatment. Transurethral resection specimens were reassessed by two experienced urological pathologists for tumor grade according to the World Health Organization 1973 classification, metric T1 substage, lamina propria invasion pattern and associated carcinoma in situ. The median follow-up period was 42 months (interquartile range 25-72 months). In addition to Kaplan-Meier analyses, uni-and multivariable Cox regression analyses were used to compare progression-free survival, cancer-specific survival and overall survival for the studied parameters comparing two subcohorts. Results: While in patients after instillation treatment no examined feature was shown as an independent predictor for prognosis, there were predictive histopathological features in multivariable Cox regression analyses in instillation treatment-na€ ıve patients: associated carcinoma in situ (hazard ratio 2.278, 95% confidence interval 1.119-4.634, P = 0.023) and World Health Organization 1973 grade 3 (hazard ratio 2.950, 95% confidence interval 1.021-8.536, P = 0.046) for worse progression-free survival, infiltrative lamina propria tumor pattern for worse cancer-specific survival (hazard ratio 2.369, 95% confidence interval 1.034-5.429, P = 0.042) and overall survival (hazard ratio 1.049, 95% confidence interval 1.024-1.075, P = 0.001).
Introduction
Approximately 70-80% of urothelial BCs are NMIBC at the initial diagnosis. 1 NMIBC is a heterogeneous group with varying oncological outcomes. Low-grade Ta NMIBC rarely progresses, but requires frequent cystoscopic surveillance and treatment. 1, 2 Conversely, HG NMIBC has significant progression and death rates. In particular for T1-HG BC, comprising 25% of NMIBC, discrimination of potentially progressive and fatal BC is challenging. and possibly lethal BC. These two recent studies carried out an in-depth analysis of prognostic factors for T1-HG BC patients. 4 , 5 Gontero et al. collected individual patient data on 2451, mostly primary, T1-HG BCs. 4 The variables that were linked to progression and worse CSS in multivariable analysis were older age (≥70 years), tumor size (≥3 cm) and associated CIS. Martin-Doyle et al. carried out a prognostic factor meta-analysis using the data of 33 studies (n = 8880). 5 Their analysis showed that the substage (6/33 studies; n = 785) had the highest impact on the progression of T1-HG BC. 5 Other variables that were also associated with clinical outcome were older age, non-use of BCG, LVI, tumor size (≥3 cm) and associated CIS. 5 The aim of the present study was to investigate established prognostic factors and relatively new histopathological tumor characteristics including metric substage and lamina propria invasion patterns in a large series of T1-HG BC from a single center in whom systematic re-TUR and histopathological reassessment of all resection specimens was carried out.
Methods

Patient characteristics
After informed consent, we collected archived tumor tissue slides of 322 patients initially diagnosed between 1989 and 2012 and later reassessed as T1-HG BC by TUR of the bladder tumor(s) and re-TUR 4-6 weeks afterwards. Follow up was generally carried out according to the EAU guidelines, 2 and instillation treatments were carried out in the outpatient clinic according to the physician's discretion. Stage progression towards muscle-invasive BC resulted in an advice for RC. We retrospectively assessed patients' histopathological and clinical data, and collected information regarding disease progression to muscle-invasive BC, PFS, CSS and OS. Patients without progression were censored at the date of their last follow-up appointment or death. The median follow-up period was 42 months (IQR 25-72 months).
Histopathological assessment
All BCs were diagnosed according to the TNM classification and EAU guidelines.
2 A multi-reviewer assessment involving experienced uropathologists (SB, AH) was carried out in order to assure the diagnosis of stage T1, and to define histological grade according to the WHO classifications of 1973 and 2004. Other histopathological and clinicopathological factors were assessed by the same reviewers as well.
Metric T1 substage (depth of invasion below or beyond 1 HPF [estimated size 0.5 mm]) was evaluated as described previously. 6 The lamina propria invasion pattern (nodular, trabecular or infiltrative) at the invasion front was also evaluated by both pathologists, and consensus was reached after discussion of discrepant cases. We evaluated all slides of the tumor, and separated pushing/trabecular invasion pattern from infiltrative pattern. The latter was defined as invasive growth of the tumor at the invasion front as small tumor cell nests or single tumor cells in at least 10% of the invasion front. It is a surrogate marker for EMT, and was also described as tumor budding in several tumor types. We included representative examples of the invasion pattern as Figure 1 . 
Statistical analysis
Statistical analyses were carried out using SPSS version 23.0 (IBM Deutschland GmbH, Ehningen, Germany). PFS, CSS and OS rates for the variables tested were calculated by Kaplan-Meier analysis and log-rank tests. Univariable and multivariable Cox regression analyses were used to assess the value of the various clinical and histopathological parameters for PFS, CSS and OS in separate cohorts of patients after instillation treatment and without instillation treatment. A P-value <0.05 was considered statistically significant.
Results
Patient characteristics
The median age of the 322 T1-HG BC patients included in the present study was 72 years (IQR 64-79 years). Of these patients, 78% were men. According to the WHO 1973 classification system, the grade was G2 in 30% and G3 in 70%. Solid tumors were reported in 17% of cases. Associated CIS was found in 29% of patients. Multifocal tumors were present in 27%, and tumor size was ≥3 cm in 57% of the T1-HG BC patients. The lamina propria invasion pattern was infiltrative in 22% and non-infiltrative (nodular 64%; trabecular 14%) in 78%. Metric stage pT1 substaging was <1 HPF in 60 patients (19%) and ≥1 HPF in 262 patients (81%). These and other patient and tumor characteristics are summarized in Table 1 .
Treatment and course of patients
Instillation treatment was administered in 57% of the patients. Correlation of instillation treatment with patient and tumor characteristics showed a statistically significantly higher rate of treatment only in patients with associated CIS, multifocal tumors and tumor size ≥3 cm according to the European Organization for Research and Treatment of Cancer risk tables for NMIBC, 2 but was not associated with sex, age, WHO grading classification, metric substaging, growth pattern and growth pattern at the tumor invasion front. Patients after instillation treatment showed better 5-year PFS (83% vs 72%, P = 0.003), CSS (90% vs 74%, P = 0.001) and OS (65% vs 40%, P < 0.001) than instillation treatment-na€ ıve patients in Kaplan-Meier analysis.
Progressive disease to muscle-invasive BC occurred in 19% of patients, and 16% of patients underwent RC due to progression in the follow-up period (Table 1) . Of the 322 studied T1-HG patients, 37 (12%) died of BC and 29% died of causes other than BC.
Kaplan-Meier analyses and univariable regression analyses for PFS, CSS and OS
To exclude potential bias, we did not include the three mentioned features, CIS, focality and tumor size, that were statistically significantly associated with instillation treatment for Kaplan-Meier analysis. A statistically significantly improved 5-year PFS of 90% versus 74%, P = 0.007 (log-rank test) was found for patients with G2 (WHO 1973 classification) tumors, non-infiltrative (nodular or trabecular) lamina propria invasion pattern (81% vs 69%, P = 0.015) and micro-invasive (within 1 HPF) metric substage (86% vs 77%, P = 0.035). The corresponding Kaplan-Meier curves of these significant predictors of PFS are shown in Figure 2 . Regarding CSS, non-infiltrative (nodular or trabecular) lamina propria invasion pattern (86% vs 70%, P = 0.006) and WHO 1973 G2 tumors (94% vs 79%, P = 0.022) were significantly associated with better CSS. The corresponding Kaplan-Meier curves of these significant predictors of CSS are shown in Figure 3 .
Regarding OS, non-infiltrative lamina propria invasion pattern showed statistically significantly better survival than infiltrative invasion pattern (59% vs 38%, P = 0.001), as shown in Figure 4 .
Univariate regression analyses of these and other clinicopathological features separated for patients after and without instillation treatment is shown in Tables 2 and 3 . Table 2 ). Multivariable Cox regression analysis of the significant parameters in univariable analyses of patients after instillation treatment did only reveal older age as independent predictor for CSS (HR 1.076, 95% CI 1.017-1.138, P = 0.011) and OS (HR 1.071, 95% CI 1.042-1.100, P < 0.001; Table 3 ).
Discussion
The management of stage T1 BC is controversial, and currently consists of treatments at two ends of a spectrum; that is, TUR with adjuvant instillations or RC. 1,2 The conservative approach might lead more often to progression and possibly death from BC. In contrast, RC is associated with significant morbidity and quality of life impairment, and might be considered as overtreatment for non-progressive disease. Therefore, clinicians need reliable variables, which provide prognostic information to guide decision-making in this difficult subgroup of stage T1-HG BC patients. In the present study on 322 T1-HG BC patients who all had a re-TUR before conservative management, we identified lamina propria invasion pattern, WHO 1973 grade and metric stage pT1 substaging as significant variables to predict clinical outcome for T1-HG BC patients in Kaplan-Meier analysis. In multivariable analysis of the clinical and histopathological features for CSS, the infiltrative lamina propria invasion pattern proved to be the only independent prognostic factor for worse outcome in patients without instillation treatment after TUR, and there was a trend for this feature regarding OS. Together with associated CIS and grade 3 (after WHO classification 1973), which were independent predictors of PFS, this feature should lead at least to instillation treatment with BCG. In the subcohort of patients after this treatment, there was no clinical and histopathological feature with independent prediction of PFS, CSS and OS in multivariable Cox regression analyses despite older age.
The lamina propria invasion pattern was proposed to be separated into three different categories; that is, nodular, trabecular and infiltrative. 6 This pattern can be easily investigated at the invasion front of the tumor. The infiltrative pattern was found to be associated with worse clinical outcome for muscle-invasive BC, 7 upper tract urothelial cancer 8 and stage T1 BC 6 in three separate studies. We confirmed its prognostic significance in the present study for instillationna€ ıve patients. Although the number of reports on the invasion pattern is low, we believe that this parameter might be added to the standard pathology report in the case of lamina propria invasion. The clinical relevance of lamina propria invasion patterns indicates that the EMT plays a relevant role in progression and survival of NMIBC. For example, Hedegaard et al. showed that a high expression of EMT driving transcriptional factors, such as ZEB1, ZEB2 and TWIST1, is present in a subgroup of NMIBC with a worse prognosis. 9 The most important histomorphological surrogate for EMT is the so-called tumor budding, which is a well-defined independent risk factor in colorectal carcinomas, 10 but also in squamous cell carcinomas of the oropharynx and lung. 11, 12 For the first time, in 2016, Fukumoto et al. showed that the presence of tumor budding at the invasion border is a highly prognostic risk factor for an adverse PFS in NMIBC. 13, 14 Taken together, the prognostic value of invasion border configuration in NMIBC is probably derived from differential activation of the EMT program, and could represent a powerful histomorphological surrogate for the grade of EMT activation. However, the correlation between EMT, the presence of tumor budding, the configuration of the tumor invasion border and the differential expression of EMT driving transcription factors in NMIBC requires further combined histopathological and molecular studies. Quantification schemes for tumor budding developed for colorectal cancer should be adjusted to urothelial carcinoma and prospectively tested.
Associated CIS, older age and tumor size ≥3 cm have been identified as important prognostic factors for T1 BC in two recent reports with large patient numbers. 4, 5 Several smaller studies confirmed the prognostic value of these three parameters. 6, 15, 16 This suggests that associated CIS, age and size could be included in risk stratification models to identify patients who might benefit from immediate RC. 4, 16 In the present analysis of instillation treatment-na€ ıve patients, we could at least confirm associated CIS as an independent predictor for progression in multivariable Cox regression analysis.
Tumor pattern (papillary/solid) and LVI have been suggested as prognostic parameters in T1 BC. 5, 17 For example, LVI was prognostic for CSS of T1-HG BC, but not for progression in the recently prognostic factor meta-analysis of Martin-Doyle et al. 5 Using Swedish population-based data of 121 T1 BC patients, Andius et al. reported that LVI and tumor pattern were associated with clinical outcome, whereas the depth of invasion (T1a/b) was not. 17 Orsola et al. recently reported the opposite in a prospective study with 200 T1-HG BC patients. 16 They found that LVI and tumor pattern were not as prognostic as depth of invasion (T1a/b). 16 In the present study with 322 patients, tumor pattern was not prognostic. Because the incidence of the solid tumor pattern and LVI are relatively low in T1 BC, larger T1 series might give us more reliable data on these two parameters.
Grade is strongly associated with prognosis (especially PFS and CSS), and it has been extensively studied in NMIBC. 1, 2 In 2004, a two-tiered new classification system for grade (low vs high grade) was accepted by the WHO to improve reproducibility and prognosis compared with the "old" WHO 1973 classification system. 18 For the prediction of PFS and CSS in T1 BC patients, the discriminative power of grade got lost in the WHO 2004 system, as the large majority of T1 BC are classified as HG. 3, 19 Looking at the results of the present study and many other reports, the WHO 1973 classification system can be considered superior to WHO 2004 for T1 BC. 3, 6, 9, [19] [20] [21] This is the main reason why the EAU still holds onto WHO 1973 in their NMIBC guidelines. 2 Substaging is another concept to possibly discern indolent from aggressive T1 BC. Stage T1 substage has been shown to be highly prognostic in many studies. [1] [2] [3] 5, 6, 9, 16, 20, 21 Traditionally, T1 BC has been substaged according to invasion above (T1a) and in/beyond (T1b/c) the muscularis mucosae, a thin layer of smooth muscle fibers within the lamina propria. Despite its prognostic value, T1ab substage has not been adopted by clinical guidelines. 1, 2 In the recent WHO classification published in 2016, it was stated that substaging in T1 BC is clinically relevant, but no agreement of specific details of substaging was reached. 2 The main reason was a lack of consensus among pathologists regarding the identification of the lamina muscularis mucosae at the tumor invasion front. Metric T1 substage based on invasion below or beyond 0.5 mm (1 HPF) proved to be user-friendly and highly effective to predict prognosis in several studies. 3, 6, 15, 22 In the present study, metric T1 substage was prognostic for PFS in Kaplan-Meier analysis, but not in the two subcohorts, as an independent predictor of our end-points. Metric substage has the potential to be incorporated in TNM classification system for urinary BC if further multicenter validation confirms its reproducibility and prognostic value.
Certain limitations regarding the present study need to be mentioned. It was a retrospective, single-center study with a relatively short follow-up period. As a consequence, a lower number of events than anticipated for reliable multivariable analyses, especially for CSS, were noted. In addition, adjuvant instillation therapy was not given to all patients as per the EAU guideline recommendations. In contrast, it was recently shown that guideline adherence to administer BCG therapy for high-risk NMIBC is 65% in Europe and 29% in North America. 23 A very recent study of two Japanese NMIBC cohorts of 1497 patients by Ieda et al., including 490 T1 BC and 52 pure CIS patients, revealed bladder instillation treatment with various compounds in just 38% of the total cohort. 24 This indicates that our rate of instillation treatment of 57% more or less match with these "real world data." Because of this nearly 1:1 situation of patients after instillation treatment and instillation-na€ ıve patients, we were able to make an analysis of these subcohorts. Further strengths of the present study include a re-TUR in all patients and thorough pathology review. In conclusion, we identified several prognostic factors to predict the clinical course of T1-HG BC. Among these, WHO 1973 grade and associated CIS were already found in earlier studies. In particular, lamina propria invasion pattern was found to be a very promising pathological marker regarding CSS, and there was a trend to be so for OS at least in instillation treatment-na€ ıve patients. Additional multicenter studies are required to confirm or refute the prognostic value of these parameters. The ultimate challenge in stage T1 BC is to identify the patients who can be managed conservatively, and to accurately select the patients who require RC before progression and metastasis occur. One of our most important conclusions remains the clear confirmation of guideline recommendations that patients with stage T1 BC should at least undergo instillation treatment.
